Epitalon: Molecular Structure

Molecular Structure and Properties#

Epitalon (Epithalon, Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG in single-letter code), a molecular weight of 390.3 Da, and the molecular formula C14H22N4O9. Its CAS registry number is 307297-39-8. The molecule was designed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the peptide fraction identified in Epithalamin, a crude extract derived from bovine pineal gland tissue.

Amino Acid Sequence#

Primary Structure#

Epitalon consists of just four amino acid residues in the following order:

1. Alanine (Ala, A) -- Position 1, N-terminal. A small, nonpolar, aliphatic amino acid with a methyl side chain. Alanine contributes minimal steric bulk and is conformationally flexible.
2. Glutamic acid (Glu, E) -- Position 2. An acidic amino acid with a gamma-carboxyl group (pKa approximately 4.1). At physiological pH, this residue carries a negative charge.
3. Aspartic acid (Asp, D) -- Position 3. An acidic amino acid with a beta-carboxyl group (pKa approximately 3.9). At physiological pH, this residue also carries a negative charge.
4. Glycine (Gly, G) -- Position 4, C-terminal. The simplest amino acid, lacking a side chain entirely. Glycine provides maximal backbone flexibility and contributes the least steric constraint of any residue.

Charge and Physicochemical Properties#

The sequence AEDG is notable for its strongly acidic character. At physiological pH (approximately 7.4), the predicted net charge is approximately -3, arising from the deprotonated side chains of Glu2 and Asp3, the deprotonated C-terminal carboxyl group, and the partially protonated N-terminal amino group. The theoretical isoelectric point (pI) is estimated at approximately 3.1 to 3.3, reflecting the dominance of acidic residues.

Structural Simplicity#

At only four residues and 390.3 Da, Epitalon is among the smallest peptides proposed to have bioregulatory activity. For comparison, most characterized bioactive peptides range from 5 to 50 amino acids (roughly 500 to 5,500 Da), and most known transcription-regulating proteins are orders of magnitude larger. The extreme simplicity of the AEDG sequence raises questions in mainstream structural biology about its capacity for specific molecular recognition, particularly the proposed direct interactions with DNA or chromatin structures that would require sequence-specific binding contacts typically mediated by large protein domains such as zinc fingers, leucine zippers, or helix-turn-helix motifs.

The small size means Epitalon lacks defined secondary structure in solution. A four-residue peptide does not have sufficient length to form stable alpha-helices (which require a minimum of approximately 4 to 5 residues for a single turn) or beta-sheets. The backbone is expected to adopt a largely extended or random coil conformation, with considerable flexibility conferred by the terminal glycine residue.

Comparison with Epithalamin#

Epithalamin is the crude peptide extract originally isolated from bovine pineal gland tissue by the Khavinson group. It contains a heterogeneous mixture of peptides and potentially other biomolecules present in pineal tissue. Epitalon was identified as the proposed principal active component of this extract and was synthesized as a chemically defined tetrapeptide to replace the natural preparation.

The Khavinson group has reported similar biological activities for both preparations, suggesting that the AEDG sequence captures the principal bioactive component of the pineal extract. However, the possibility that Epithalamin contains additional active components beyond the AEDG sequence has not been definitively excluded by comparative studies. The transition from crude extract to defined synthetic peptide represents a standard pharmacological refinement, though independent validation of equivalent bioactivity remains limited.

Stability and Solubility#

No formal ICH-style stability studies for Epitalon have been published in the peer-reviewed literature. The following properties can be inferred from the sequence and general peptide chemistry principles:

• Aqueous solubility: Expected to be high given the strongly polar and charged character of the molecule. The two acidic side chains and the absence of hydrophobic residues predict good solubility in aqueous buffers at neutral to basic pH.
• pH sensitivity: The charge state of Epitalon is pH-dependent. Below pH 3, the acidic side chains become protonated and the molecule approaches net neutrality; at neutral and basic pH, the molecule carries a strong negative charge.
• Proteolytic susceptibility: As a short, unmodified peptide, Epitalon is expected to be rapidly degraded by endogenous peptidases in biological fluids. Tetrapeptides are typically cleared within minutes in plasma due to the action of aminopeptidases, carboxypeptidases, and endopeptidases. No pharmacokinetic data establishing the plasma half-life of Epitalon in any species have been published.
• Thermal stability: Small peptides are generally stable to moderate heating in aqueous solution, though prolonged exposure to elevated temperatures can promote deamidation of Asn/Gln residues or cleavage of Asp-X bonds. Epitalon contains an Asp residue at position 3, which may be susceptible to aspartimide formation or peptide bond hydrolysis under acidic conditions.
• Storage: In the absence of published stability data, standard peptide handling practices would recommend storage of lyophilized Epitalon at -20 degrees Celsius, with reconstituted solutions stored at 2 to 8 degrees Celsius and used within a limited timeframe.

Pharmacokinetics#

No primary pharmacokinetic studies of Epitalon have been published in the peer-reviewed literature. Based on the known properties of unmodified tetrapeptides, the following can be inferred:

• Half-life: Expected to be very short, on the order of minutes, due to rapid proteolytic degradation. Tetrapeptides lack the structural features (cyclization, D-amino acids, PEGylation, or other modifications) that confer protease resistance to therapeutic peptides.
• Absorption: Following subcutaneous or intramuscular injection, absorption into the systemic circulation is expected to be rapid but with uncertain bioavailability given rapid local degradation.
• Distribution: At 390.3 Da, Epitalon is well below the molecular weight threshold for renal filtration and would be expected to distribute widely but be eliminated rapidly.
• Metabolism: Degradation to individual amino acids (alanine, glutamic acid, aspartic acid, glycine) by ubiquitous peptidases, with the released amino acids entering normal metabolic pools.

The absence of published pharmacokinetic data represents a significant gap in the characterization of Epitalon as a potential bioactive agent. Without established plasma concentrations, tissue distribution, and exposure-response relationships, the pharmacological basis for any observed biological effects remains undefined.

Evidence Gaps#

• No published pharmacokinetic or pharmacodynamic data in any species
• No structural biology studies (NMR, X-ray crystallography) of Epitalon-DNA or Epitalon-protein interactions
• No formal stability studies under ICH guidelines
• No comparative bioactivity studies between Epithalamin and Epitalon under standardized conditions
• The proposed mechanism of direct peptide-DNA interaction lacks structural evidence from independent laboratories
• No published data on solution conformation or aggregation behavior

Related Reading#

• Epitalon overview and research guide
• Peptides similar to Epitalon
• Epitalon research evidence